• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD face a difficult decision on whether to keep or stop taking ADHD medication during pregnancy and breastfeeding. There aren't many studies regarding how exposure over time may affect a fetus.

A study recently published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological disorders like hearing loss or vision, febrile seizures or IQ impairment. The authors acknowledge that further high-quality studies are required.

Risk/Benefit Analysis

Women who are expecting and taking ADHD medication must evaluate the benefits of using it against the possible risks for the fetus. Doctors don't have the necessary data to make unequivocal recommendations but they can provide information about risks and benefits that aid pregnant women in making informed decisions.

A study published in Molecular Psychiatry found that women who used ADHD medications in early pregnancy did not have a significantly increased risk of fetal heart malformations or major structural birth defects. Researchers used a large sample-based case control study to examine the prevalence of major structural defects in infants born to mothers who used stimulants during pregnancy. Clinical geneticists and pediatric cardiologists reviewed the cases to ensure an accurate classification of the cases and to reduce the possibility of bias.

However, the researchers' study had its limitations. Researchers were unable to, in the first place to differentiate the effects of the medication from the disorder. This limitation makes it difficult to determine whether the limited associations observed in the exposed groups result from medication use or the confounding effect of comorbidities. The researchers did not study long-term outcomes for the offspring.

The study showed that infants whose mothers had taken Adhd Medication pregnancy medication during pregnancy had a slightly higher risk of admission to the neonatal care unit (NICU) as compared to mothers who did not use any medication during pregnancy, or had stopped taking their medication before or during pregnancy. This increase was caused by central nervous system disorders. The increased risk of admission was not affected by the stimulant medication used during pregnancy.

Women who were taking stimulant ADHD medication during pregnancy were also at an elevated risk of having a caesarean birth or having a child with a low Apgar score (less than 7). These risks did not appear to be affected by the type of medication that was used during pregnancy.

The research suggests that the low risk associated with the use of ADHD medications during the early stages of pregnancy could be offset by the greater benefits to both the mother and child of continuing treatment for the woman's disorder. Physicians should discuss this with their patients and, where they are able, assist them in developing strategies for improving their coping skills that can lessen the negative impact of her condition on her daily functioning and relationships.

medication for adhd and anxiety Interactions

Many doctors are confronted with the dilemma of whether to continue treatment or stop it during pregnancy as more women are diagnosed with ADHD. These decisions are often made without clear and authoritative evidence. Instead, physicians must consider their own expertise in conjunction with the experiences of other physicians and the research that has been conducted on the subject.

Particularly, the subject of potential risks for the baby can be tricky. Many studies on this issue are based on observational evidence instead of controlled research and their findings are often contradictory. Additionally, the majority of studies limit their analysis to live births, which could underestimate the severity of teratogenic effects that could result in abortion or termination of the pregnancy. The study discussed in the journal club addresses these issues by analyzing both the data from deceased and live births.

Conclusion: While some studies have shown a positive correlation between ADHD medications and certain birth defects, other studies have not established a link. Most studies have shown an unintended, or slightly negative, impact. In every case an in-depth analysis of the risks and benefits should be conducted.

It can be challenging, if not impossible for women with ADHD to stop taking their medication. In fact, in a recent article in Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can cause depression, feelings of isolation, and family conflict for patients with adult adhd medication uk. Furthermore, a loss of medication can affect the ability to perform jobs and drive safely, which are important aspects of a normal life for many people suffering from ADHD.

She recommends women who are uncertain about whether to keep or stop medication in light of their pregnancy should consider the possibility of educating friends, family members and colleagues on the condition, its impact on daily functioning, and on the advantages of continuing the current treatment regimen. It can also help a woman feel supported in her decision. Some medications can pass through the placenta. If a patient decides to stop taking her ADHD medication while pregnant and breastfeeding, it is important to be aware that the medication could be passed on to her baby.

Risk of Birth Defects

As the use and use of ADHD medications to treat the symptoms of attention deficit hyperactivity disorder (ADHD) is increasing, so does concern about the possible effects of the drugs on the fetuses. A recent study published in the journal Molecular Psychiatry adds to the body of knowledge about this subject. Researchers used two massive datasets to analyze more than 4.3 million pregnant women and determine if stimulant medication use increased the risk of birth defects. Researchers found that while the risk overall is low, the first trimester ADHD medication use was associated with slightly higher rates of certain heart defects, like ventriculoseptal defects.

The authors of the study found no connection between the use of early medications and other congenital anomalies, like facial clefting, or club foot. The results are in the same vein as previous studies that showed the existence of a slight, but significant increase in cardiac malformations for women who began taking ADHD medication before pregnancy. The risk increased in the latter stages of pregnancy, when a lot of women stopped taking their medication.

Women who were taking ADHD medication during the first trimester were more likely to require a caesarean birth or have a low Apgar after delivery, and have a baby that needed help breathing at birth. The researchers of the study could not remove bias in selection since they limited the study to women who did not have any other medical conditions that might have contributed to the findings.

The researchers hope that their research will aid in the clinical decisions of doctors who treat pregnant women. The researchers advise that, while discussing benefits and risks are crucial, the decision about whether to continue or stop taking medication should be based on the severity of each woman's ADHD symptoms and her requirements.

The authors warn that, even though stopping the medication is a possibility to consider, it is not advised due to the high prevalence of depression and mental health issues in women who are expecting or have recently given birth. Further, research shows that women who stop taking their medications will have a tough adjustment to life without them once the baby is born.

Nursing

The responsibilities of a new mother can be overwhelming. Women who suffer from ADHD who have to manage their symptoms while attending physician appointments, preparing for the arrival of their child and getting used to new routines at home are often faced with a number of difficulties. This is why many women choose to continue taking their ADHD medications throughout the course of pregnancy.

The risk to breastfeeding infant is minimal because the majority of stimulant medication passes through breast milk at low levels. However, the rate of medication exposure to the newborn may differ based on dosage, how often it is taken and the time of day the medication is administered. Additionally, different medications are introduced into the baby's system through the gastrointestinal tract, or through breast milk. The effect on a newborn's health is not completely known.

Some doctors may decide to stop stimulant medications during a woman's pregnancy due to the lack of research. It's a difficult choice for the woman who must weigh the benefits of continuing her medication against the risk to the foetus. Until more information is available, doctors should inquire with all pregnant patients about their experience with ADHD and whether they plan or are taking to take medication during the perinatal period.

A increasing number of studies have revealed that women can continue to take their ADHD medication while they are pregnant and nursing. In the end, an increasing number of patients choose to do so and in consultation with their doctor they have found that the benefits of continuing their current medication outweigh any risks.

It is crucial for women suffering from ADHD who are considering breastfeeding to seek out a specialist psychiatrist's guidance prior to becoming pregnant. They should discuss their medication with their physician and discuss the pros and cons of continued treatment, including non-pharmacological management strategies. Psychoeducation is also necessary to help pregnant women with ADHD understand the symptoms and underlying disorder. They should also be informed about treatment options and reinforce the coping mechanisms. This should be a multidisciplinary process including obstetricians, GPs and psychiatrists. The pregnancy counselling should consist of the discussion of a treatment plan for both mother and child, as well as monitoring for signs of deterioration, and the need for adjustments to the medication regimen.